This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Katrina Bykova, PhD
Group Leader, Discovery Biology & Pharmacology at Xencor


Katrina Bykova, PhD, is a Group Leader in the Discovery Biology & Pharmacology department at Xencor, Inc. Her work at Xencor is focused on development of bispecific antibodies that are designed to modulate patient immune system to enhance the anti-tumor response. Prior to joining Xencor Katrina led target discovery efforts and therapeutic programs in the immune-oncology and autoimmunity fields at BMS and Amgen where she worked on T cell modulation and pathways targeting a myeloid component of the tumor microenvironment. Katrina holds a PhD in Pharmacology and Toxicology from University of California.

Agenda Sessions

  • Synergistic Combination of Trispecific Natural Killer Cell Engagers with Proinflammatory Cytokines